Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients

The FDA has signed off Phase 1b/2 trial for Moleculin Biotech Inc's MBRX Annamycin to treat soft tissue sarcoma lung metastases.
Annamycin is the company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin.
It has also demonstrated a lack of cardiotoxicity in recently conducted human clinical trials to treat acute myeloid leukemia (AML).
Phase 1b portion of the trial will determine the maximum-tolerated dose and safety of Annamycin, and Phase 2 will explore the efficacy of Annamycin as a single agent.
A maximum of 25 subjects will be enrolled at the RP2D to evaluate efficacy further.
The company also expects a second Phase 1b/2 trial of Annamycin in sarcoma lung metastases to be initiated in 2021.
Price Action: MBRX shares are up 0.69% at $3.64 during the market session on the last check Tuesday.